社区实践中筛查乳腺MR成像的性能基准
该研究基于乳腺癌症监测联盟(BCSC)2005至2013年5343名女性的8387次筛查MR检查,对照BI-RADS第五版基准评估性能。癌症检出率为每1000次筛查17例(95%CI 15-20),低于BI-RADS基准20-30;活检推荐阳性预测值为19%(95%CI 16%-22%),敏感性81%(95%CI 75%-86%),特异性83%(95%CI 82%-84%)。作者结论认为BCSC筛查MR的解释性能满足多数BI-RADS基准,其余指标接近基准水平。
要点
- 筛查MR癌症检出率为每1000次检查17例,低于BI-RADS基准20-30例。
- 活检推荐阳性预测值19%,超过BI-RADS基准15%。
- 敏感性81%接近基准>80%,特异性83%低于基准85%-90%。
核心结论
- BCSC社区实践中的筛查MR解释性能满足多数BI-RADS基准,其余指标接近基准水平。
研究设计与样本
- 经机构审查委员会批准并符合HIPAA的BCSC筛查MR检查研究,纳入2005至2013年5343名女性的8387次筛查MR检查,链接区域SEER登记、州肿瘤登记和病理信息数据库以识别乳腺癌病例及肿瘤特征。
关键影像表现/征象
- 筛查MR检出146例癌症,另识别35例间期癌,共181例(原位54例、浸润性125例、状态未知2例)。
- 浸润性癌中位肿瘤大小为10 mm,88%为淋巴结阴性。
诊断标准与关键数值
- 癌症检出率为每1000次筛查17例(95%CI 15-20),BI-RADS基准为每1000次筛查20-30例。
- 活检推荐阳性预测值为19%(95%CI 16%-22%),BI-RADS基准为15%。
- 敏感性为81%(95%CI 75%-86%),BI-RADS基准为>80%。
- 特异性为83%(95%CI 82%-84%),BI-RADS基准为85%-90%。
临床应用与阅片要点
- 研究基于BCSC社区实践数据,可按BI-RADS第五版指标对照评估筛查MR性能。
- 筛查MR的癌症检出率低于BI-RADS基准,活检推荐阳性预测值高于基准。
- 敏感性接近BI-RADS基准,特异性低于BI-RADS基准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To compare screening magnetic resonance (MR) imaging performance in the Breast Cancer Surveillance Consortium (BCSC) with Breast Imaging Reporting and Data System (BI-RADS) benchmarks. Materials and Methods This study was approved by the institutional review board and compliant with HIPAA and included BCSC screening MR examinations collected between 2005 and 2013 from 5343 women (8387 MR examinations) linked to regional Surveillance, Epidemiology, and End Results program registries, state tumor registries, and pathologic information databases that identified breast cancer cases and tumor characteristics. Clinical, demographic, and imaging characteristics were assessed. Performance measures were calculated according to BI-RADS fifth edition and included cancer detection rate (CDR), positive predictive value of biopsy recommendation (PPV2), sensitivity, and specificity. Results The median patient age was 52 years; 52% of MR examinations were performed in women with a first-degree family history of breast cancer, 46% in women with a personal history of breast cancer, and 15% in women with both risk factors. Screening MR imaging depicted 146 cancers, and 35 interval cancers were identified (181 total-54 in situ, 125 invasive, and two status unknown). The CDR was 17 per 1000 screening examinations (95% confidence interval [CI]: 15, 20 per 1000 screening examinations; BI-RADS benchmark, 20-30 per 1000 screening examinations). PPV2 was 19% (95% CI: 16%, 22%; benchmark, 15%). Sensitivity was 81% (95% CI: 75%, 86%; benchmark, >80%), and specificity was 83% (95% CI: 82%, 84%; benchmark, 85%-90%). The median tumor size of invasive cancers was 10 mm; 88% were node negative. Conclusion The interpretative performance of screening MR imaging in the BCSC meets most BI-RADS benchmarks and approaches benchmark levels for remaining measures. Clinical practice performance data can inform ongoing benchmark development and help identify areas for quality improvement. © RSNA, 2017.
引用
- Lee JM, Ichikawa L, Valencia E, et al. Performance Benchmarks for Screening Breast MR Imaging in Community Practice. Radiology. 2017. PMID: 28582633. doi:10.1148/radiol.2017162033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。